We are live on !
Find out more
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.39B
AUM Growth
+$491M
(+17%)
Cap. Flow
-$110M
Cap. Flow % of AUM
Cap. Flow %
-3.26%
Top 10 Holdings %
Top 10 Hldgs %
67.91%
Holding
89
New
9
Increased
10
Reduced
15
Closed
13
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
1.5
years
Top 20 Avg Time Held
Equity + Options
1.3
years
Avg Time Held Equity only
1.2
years
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpringWorks Therapeutics
SWTX
|
+$99.2M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$75.1M |
| 3 |
Gossamer Bio
GOSS
|
+$51.6M |
| 4 |
Kymera Therapeutics
KYMR
|
+$21M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$118M |
| 2 |
Revolution Medicines
RVMD
|
+$54.4M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$53.7M |
| 4 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$43.5M |
| 5 |
argenx
ARGX
|
+$39.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.27% |
| 2 | Financials | 0.56% |
| 3 | Miscellaneous | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Voyager Therapeutics
VYGR
$117M
| $28.1M | 0.83% |
4,753,907
| – | – |
2021 Q3
4 quarters
|
|
27
DELISTED
Crinetics Pharmaceuticals
CRNX
| $26.1M | 0.77% |
1,330,263
| – | – |
2021 Q4
3 quarters
|
|
28
Janux Therapeutics
JANX
$1.01B
| $19.2M | 0.57% |
1,421,319
| – | – |
2021 Q2
5 quarters
|
|
|
29
Kymera Therapeutics
KYMR
$8.71B
| $17.3M | 0.51% |
+796,093
| New | +$21M |
2022 Q3
0 quarters
|
|
30
Tango Therapeutics
TNGX
$3.72B
| $15.2M | 0.45% |
4,201,414
+1,899,349
| +83% | +$8.11M |
2020 Q3
8 quarters
|
|
31
Cullinan Oncology
CGEM
$832M
| $14.7M | 0.43% |
1,143,218
-26,671
| -2% | -$359K |
2022 Q2
1 quarter
|
|
32
DELISTED
Ventyx Biosciences
VTYX
| $14M | 0.41% |
400,000
-900,000
| -69% | -$19.9M |
2021 Q4
3 quarters
|
|
|
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $13.6M | 0.4% |
690,000
| – | – |
2022 Q1
2 quarters
|
|
|
AKUS
34
DELISTED
Akouos Inc
AKUS
| $13.4M | 0.39% |
1,975,984
| – | – |
2020 Q2
9 quarters
|
|
|
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
| $13M | 0.38% |
3,236,352
+2,944,032
| +1,007% | +$13.5M |
2021 Q2
5 quarters
|
|
36
Ovid Therapeutics
OVID
$420M
| $11.3M | 0.33% |
6,117,400
| – | – |
2021 Q1
6 quarters
|
|
37
Oric Pharmaceuticals
ORIC
$1.28B
| $10.9M | 0.32% |
3,418,068
| – | – |
2020 Q2
9 quarters
|
|
38
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $9.36M | 0.28% |
+2,650,000
| New | +$8.76M |
2022 Q3
0 quarters
|
|
39
Arcutis Biotherapeutics
ARQT
$3.62B
| $7.94M | 0.23% |
415,322
-480,181
| -54% | -$10.9M |
2022 Q1
2 quarters
|
|
|
NGM
40
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $7.08M | 0.21% |
541,108
| – | – |
2022 Q1
2 quarters
|
|
41
DELISTED
HOOKIPA Pharma
HOOK
| $6.7M | 0.2% |
500,000
| – | – |
2022 Q1
2 quarters
|
|
42
Precision BioSciences
DTIL
$159M
| $6.55M | 0.19% |
167,866
| – | – |
2022 Q2
1 quarter
|
|
|
43
argenx
ARGX
$51.5B
| $6.19M | 0.18% |
17,527
-107,473
| -86% | -$39.8M |
2022 Q1
2 quarters
|
|
|
GRCL
44
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $6.19M | 0.18% |
1,921,310
| – | – |
2022 Q1
2 quarters
|
|
45
Cartesian Therapeutics
RNAC
$190M
| $5.74M | 0.17% |
116,667
| – | – |
2022 Q2
1 quarter
|
|
46
Geron
GERN
$752M
| $5.39M | 0.16% |
2,301,980
-11,867,008
| -84% | -$26.6M |
2022 Q1
2 quarters
|
|
|
AVEO
47
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $5.35M | 0.16% |
650,489
+3,000
| +0.5% | +$23K |
2022 Q2
1 quarter
|
|
48
Erasca
ERAS
$4.68B
| $5.29M | 0.16% |
678,441
| – | – |
2021 Q3
4 quarters
|
|
49
LENZ Therapeutics
LENZ
$103M
| $5.02M | 0.15% |
226,019
+59,993
| +36% | +$1.43M |
2021 Q4
3 quarters
|
|
|
JYAC
50
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $4.98M | 0.15% |
500,000
| – | – |
2020 Q4
7 quarters
|
|
Similar funds
EcoR1 Capital's Q3 2022 Portfolio in Review
As of Q3 2022, EcoR1 Capital held 89 positions worth $3.39B, up 17% from $2.9B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
EcoR1 Capital withdrew a net $110M in Q3 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $43.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.
Against the trend, EcoR1 Capital opened a new position in SpringWorks Therapeutics worth $98.7M.
- EcoR1 Capital's largest Q3 2022 buy was SpringWorks Therapeutics: 3,460,208 shares worth $98.7M.
- EcoR1 Capital added most to Centessa Pharmaceuticals in Q3 2022, an estimated $13.5M increase.
- EcoR1 Capital's biggest Q3 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $118M.
- EcoR1 Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022, selling an estimated $43.5M.
- EcoR1 Capital's ten largest holdings make up 68% of its $3.39B portfolio in Q3 2022.
- EcoR1 Capital opened 9 new positions and closed 13 in Q3 2022.
- EcoR1 Capital's portfolio value rose 17% quarter-over-quarter to $3.39B.
Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.